Changes in Beneficial Ownership · 4
SUPERNUS PHARMACEUTICALS, INC.
SUPNNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1793654220.xml
Filing details
- Report period
- 2026-10-30
- Issuer
- SUPERNUS PHARMACEUTICALS, INC.
- Issuer CIK
- 0001356576
- Trading symbol
- SUPN
Reporting owner 1
- Name
- DEC TIMOTHY C
- Reporting owner CIK
- 0001194020
- Relationship
- Officer
- Officer title
- Senior Vice-President & CFO
- Address
- C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE, MD, 20850
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock Unit | 0 | 2026-10-30 | A · Form 4 | 70,000 | A | 0 | [F1] | [F1] | Common Stock | 70,000 | 70,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- These restricted stock units ("RSUs") are settled in common stock upon vesting, which occurs in four installments. 50% of the RSUs vest upon the closing of the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (the "Closing"). 15% of the RSUs vest upon the one-year anniversary of the Closing. 15% of the RSUs vest upon the two-year anniversary of the Closing. 20% of the RSUs vest upon the three-year anniversary of the Closing.↩ 1↩ 2
Signature 1
- Signed
- /s/ Timothy C. Dec
- Date
- 2026-11-02
Company context
Supernus, Inc. is a leading, diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases. Our commercial portfolio includes approved treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Backed by strong commercial capabilities and scientific expertise, we are committed to continuous innovation, advancing a robust pipeline of novel product candidates to deliver meaningful outcomes for CNS patients.